Properties (56)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
monoclonal antibody
|
| gptkbp:activeDuring |
bevacizumab
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:associatedWith |
improved survival rates
quality of life improvement tumor shrinkage |
| gptkbp:chemicalFormula |
C6630H10240N1710O2140S44
|
| gptkbp:clinicalTrials |
combination therapy
Phase III monotherapy |
| gptkbp:contraindication |
fatigue
headache nausea diarrhea uncontrolled hypertension proteinuria recent surgery active bleeding disorders |
| gptkbp:cultivation |
Mvasi
Zirabev |
| gptkbp:drugInterdiction |
long half-life
angiogenesis inhibition |
| gptkbp:financial_aid |
24 hours at room temperature
|
| https://www.w3.org/2000/01/rdf-schema#label |
Avastin
|
| gptkbp:influencedBy |
clinical guidelines
|
| gptkbp:is_monitored_by |
wound healing
blood pressure signs of bleeding |
| gptkbp:issuedBy |
intravenous infusion
|
| gptkbp:lastProduced |
2004
|
| gptkbp:manufacturer |
gptkb:Genentech
|
| gptkbp:marketedAs |
over 100 countries
bevacizumab |
| gptkbp:merchandise |
billions of dollars
|
| gptkbp:patentExpiration |
2020
|
| gptkbp:provides |
lung cancer
breast cancer cervical cancer colorectal cancer kidney cancer |
| gptkbp:researchAreas |
clinical trials
off-label uses |
| gptkbp:researchFocus |
new cancer therapies
combination treatments |
| gptkbp:route |
IV
|
| gptkbp:sideEffect |
hypertension
bleeding gastrointestinal perforation thromboembolism wound healing complications |
| gptkbp:storage |
refrigerated
|
| gptkbp:targets |
gptkb:VEGF
|
| gptkbp:usedFor |
treatment of cancer
|
| gptkbp:variant |
radiation therapy
chemotherapy |
| gptkbp:weight |
149 kDa
|